Quantcast

Real Time Genomics Launches Free RTG Investigator for Sequence Analysis

June 22, 2011

Software delivers genome center results in variant detection and metagenomic analysis of next generation sequencing (NGS) data. Provides unparalleled speed and sensitivity in comprehensive pipelines while supporting Illumina, Complete Genomics and Roche 454. Available immediately for free at http://www.realtimegenomics.com.

San Francisco, CA (PRWEB) June 21, 2011

Real Time Genomics, Inc., today announced the immediate availability of RTG Investigator Version 2.2, the most advanced sequence analysis software for variant detection and metagenomic analysis. For the first time, RTG software is available free for individual use to biological investigators and bioinformaticists by downloading from http://www.realtimegenomics.com. This allows use of all RTG Investigator functionality for one year running on up to five computers simultaneously. There is no restriction on the use of results obtained through analysis with the software. Researchers who are generating data for whole genome, exome or metagenomics projects can particularly benefit from using RTG Investigator. Organizations that want additional service and support, centralized deployment, and unlimited use, may license RTG Investigator on an annual subscription basis. Organizational pricing is based on production usage at competitive market rates. The software currently supports Illumina, Complete Genomics and Roche 454 high-throughput sequence data.

“Over the last several years, we’ve worked with leading genome centers and scientists to solve the debilitating problems surrounding genomic analysis,” said Phillip Whalen, Chief Executive Officer of Real Time Genomics. “By making our software free to investigators we hope to accelerate genomics and its application in medical research and other high-value areas. We’re convinced that this will have a positive influence on the field.”

RTG Investigator supports research in diverse fields, such as human health, agriculture, bio-fuels and environmental security, as well as across multiple phases of a project. Anyone starting a new project can get an immediate jump-start on pipeline development. Researchers with existing pipelines can easily apply the additional sensitivity of RTG Investigator to extract premium value from current experiments or unblock investigations that require deeper analysis than existing tools can provide.

According to George Weinstock, Associate Director, The Genome Institute and Professor of Genetics at Washington University in St. Louis, “The Human Microbiome Project presented daunting challenges that Real Time Genomics solved for us with their suite of metagenomics tools. They provided software that exceeded both our requirements for metagenomic analysis and our needs for high performance computing. RTG applies top computer science expertise to consistently deliver superior, innovative products for the analysis of sequence data, with specific attention to the challenges of dealing with large next-generation sequencing data sets. Offering these capabilities for free to individual investigators will have an explosive impact on the industry.”

The Genome Institute at Washington University is a world leader in genomics research. The Institute played a leadership role in The Human Genome Project and currently is a leading participant in The Cancer Genome Atlas (TCGA) project, the Human Microbiome Project (HMP) and the 1000 Genomes Project. Central to the Institute’s charter is to advance the state of the art in genome sequencing and its application to human health.

RTG Investigator utilizes patented and patent-pending algorithms along with other proprietary trade secrets for advanced variant detection and metagenomic analysis. Pipelines based on these algorithms produce high quality results 10-1000x faster than open source and other commercial alternatives. The resulting workflows are simple and efficient yet still achieve the most accurate results.

Algorithms developed by Real Time Genomics allow functionality not previously available from other analysis software tools, such as mapping the overlapping, gapped reads from Complete Genomics. With RTG Investigator, sequence data from Complete Genomics is processed as a standard read type, allowing full integration into the variant detection pipeline. This unique feature makes RTG Investigator the only means for a researcher to yield additional results from Complete Genomics data, using in-house compute and bioinformatics resources.

“We were looking for a way to extend the value of our investment in Complete Genomics data and Real Time Genomics delivered on that goal,” said Mark Veugelers, Integration Manager at the Vlanders Institute of Biotechnology (VIB). “RTG Investigator allows us to identify consensus variants, and provides the opportunity for additional discovery from the data delivered by Complete Genomics.”

VIB is a life sciences research institute, based in Flanders, Belgium, which performs basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications.

Another example of unique functionality is the translated nucleotide search in RTG Investigator, which runs nearly one thousand times faster than BLASTX on Illumina data. This anchors a comprehensive RTG Investigator pipeline that includes contaminant filtering, metabolic function definition, species estimation and similarity analysis. Investigators can now dramatically expand their analytical capacity in metagenomics.

Real Time Genomics (http://www.realtimegenomics.com) offers easy-to-operate sequence analysis software that delivers to genome center standards. Patented and patent-pending algorithms provide unparalleled speed and sensitivity for variant detection and metagenomic analysis with large Illumina, Complete Genomics and Roche 454 data sets. Real Time Genomics is a private, San Francisco based company.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/6/prweb8576104.htm


Source: prweb



comments powered by Disqus